7/108 sources · 4 publishersUpdated Nov 6, 13:34 UTC
Clover Health reports strong Q3 2026 results and lifts FY2026 guidance
Clover Health posted third‑quarter 2026 revenue of $759.3 million, up 53% year‑over‑year, and GAAP net income of $6.44 million, reversing a prior‑year loss. Diluted EPS was $0.01. The company raised its full‑year 2026 revenue guidance to $2.99 billion and expects GAAP profitability for the full year.
Why it matters
The raised guidance signals a clearer path to full‑year GAAP profitability, which may support the stock’s recent rally. Needham reiterated a Buy rating and a $6.00 price target, citing the profitability outlook.
Key facts
- 1Q3 2026 revenue was $759.3 million, up 53% YoY. tradingview.com
- 2GAAP net income for the quarter was $6.44 million, a reversal from a $24.38 million loss a year earlier. tradingview.com
- 3Diluted earnings per share were $0.01. tradingview.com
- 4Full‑year 2026 revenue guidance was increased to $2.99 billion. finance.yahoo.com
- 5Needham maintained a Buy rating and a $6.00 price target, noting the company is on track for its first full year of GAAP profitability in 2026. investing.com
Open questions
- Material 4 reports revenue of $2.3 billion (57% YoY) and net income of $62 million, which conflicts with the $759.3 million revenue and $6.44 million net income figures in other sources.
Summary written by AlphAI AI Desk from 8 of 8 sources. Not investment advice. Figures are as stated by the linked sources.